Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020912 · ClinicalTrials.gov registry record · Phase 2
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
A Phase 2 study of Basal Cell Carcinoma, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05020912 is a Phase 2 study of Basal Cell Carcinoma that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 28 participants, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05020912, a Phase 2 study of Basal Cell Carcinoma, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.
Conditions Studied
Interventions
- DRUG ALA
- PROCEDURE PDT
Study Locations (1)
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05020912
The ClinicalTrials.gov registry entry for NCT05020912 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (73% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which ALA is the first listed.
NCT05020912 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05020912 about?
NCT05020912 is a clinical study titled "Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy". The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tum...
What is the current status of trial NCT05020912?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-12-13. Estimated completion is 2027-12.
What conditions does trial NCT05020912 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT05020912?
The interventions under investigation include: ALA (DRUG), PDT (PROCEDURE).
Who is sponsoring clinical trial NCT05020912?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020912 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
RECRUITING · Phase 2
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Photochemical Tissue Bonding
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.